Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States
- PMID: 29152576
- PMCID: PMC5687916
- DOI: 10.1128/mSphere.00261-17
Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States
Erratum in
-
Erratum for Rajam et al., "Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States".mSphere. 2019 Jun 12;4(3):e00253-19. doi: 10.1128/mSphere.00253-19. mSphere. 2019. PMID: 31189561 Free PMC article. No abstract available.
Abstract
Neisseria meningitidis is the most common cause of bacterial meningitis in children and young adults worldwide. A 4-component vaccine against N. meningitidis serogroup B (MenB) disease (MenB-4C [Bexsero]; GSK) combining factor H binding protein (fHBP), neisserial heparin binding protein (NHBA), neisserial adhesin A (NadA), and PorA-containing outer membrane vesicles was recently approved for use in the United States and other countries worldwide. Because the public health impact of MenB-4C in the United States is unclear, we used the meningococcal antigen typing system (MATS) to assess the strain coverage in a panel of strains representative of serogroup B (NmB) disease in the United States. MATS data correlate with killing in the human complement serum bactericidal assay (hSBA) and predict the susceptibility of NmB strains to killing in the hSBA, the accepted correlate of protection for MenB-4C vaccine. A panel of 442 NmB United States clinical isolates (collected in 2000 to 2008) whose data were down weighted with respect to the Oregon outbreak was selected from the Active Bacterial Core Surveillance (ABCs; CDC, Atlanta, GA) laboratory. MATS results examined to determine strain coverage were linked to multilocus sequence typing and antigen sequence data. MATS predicted that 91% (95% confidence interval [CI95], 72% to 96%) of the NmB strains causing disease in the United States would be covered by the MenB-4C vaccine, with the estimated coverage ranging from 88% to 97% by year with no detectable temporal trend. More than half of the covered strains could be targeted by two or more antigens. NHBA conferred coverage to 83% (CI95, 45% to 93%) of the strains, followed by factor H-binding protein (fHbp), which conferred coverage to 53% (CI95, 46% to 57%); PorA, which conferred coverage to 5.9%; and NadA, which conferred coverage to 2.5% (CI95, 1.1% to 5.2%). Two major clonal complexes (CC32 and CC41/44) had 99% strain coverage. The most frequent MATS phenotypes (39%) were fHbp and NHBA double positives. MATS predicts over 90% MenB-4C strain coverage in the United States, and the prediction is stable in time and consistent among bacterial genotypes. IMPORTANCE The meningococcal antigen typing system (MATS) is an enzyme-linked immunosorbent assay (ELISA)-based system that assesses the levels of expression and immune reactivity of the three recombinant MenB-4C antigens and, in conjunction with PorA variable 2 (VR2) sequencing, provides an estimate of the susceptibility of NmB isolates to killing by MenB-4C-induced antibodies. MATS assays or similar antigen phenotype analyses assume importance under conditions in which analyses of vaccine coverage predictions are not feasible with existing strategies, including large efficacy trials or functional antibody screening of an exhaustive strain panel. MATS screening of a panel of NmB U.S. isolates (n = 442) predicts high MenB-4C vaccine coverage in the United States.
Keywords: MATS; MenB-4C; NHBA; NadA; Neisseria meningitidis; PorA; SBA; fHbp.
Figures
![FIG 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5687916/bin/sph0061724020001.gif)
![FIG 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5687916/bin/sph0061724020002.gif)
![FIG 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5687916/bin/sph0061724020003.gif)
Similar articles
-
Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland.mSphere. 2018 Aug 22;3(4):e00196-18. doi: 10.1128/mSphere.00196-18. mSphere. 2018. PMID: 30135218 Free PMC article.
-
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.Vaccine. 2013 Oct 9;31(43):4968-74. doi: 10.1016/j.vaccine.2013.08.006. Epub 2013 Aug 14. Vaccine. 2013. PMID: 23954380
-
Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness.Expert Rev Vaccines. 2023 Jan-Dec;22(1):738-748. doi: 10.1080/14760584.2023.2244596. Expert Rev Vaccines. 2023. PMID: 37622470 Review.
-
Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.Clin Vaccine Immunol. 2015 Dec;22(12):1227-34. doi: 10.1128/CVI.00474-15. Epub 2015 Sep 30. Clin Vaccine Immunol. 2015. PMID: 26424832 Free PMC article.
-
MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.Vaccine. 2015 May 28;33(23):2629-36. doi: 10.1016/j.vaccine.2015.04.015. Epub 2015 Apr 13. Vaccine. 2015. PMID: 25882169 Review.
Cited by
-
Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine.JCI Insight. 2024 Apr 11;9(10):e177182. doi: 10.1172/jci.insight.177182. JCI Insight. 2024. PMID: 38775152 Free PMC article.
-
Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.Hum Vaccin Immunother. 2023 Dec 31;19(1):2212570. doi: 10.1080/21645515.2023.2212570. Hum Vaccin Immunother. 2023. PMID: 37257838 Free PMC article. Review.
-
Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines.mSphere. 2022 Oct 26;7(5):e0038522. doi: 10.1128/msphere.00385-22. Epub 2022 Sep 21. mSphere. 2022. PMID: 36129279 Free PMC article.
-
Product review on the IMD serogroup B vaccine Bexsero®.Hum Vaccin Immunother. 2022 Dec 31;18(1):2020043. doi: 10.1080/21645515.2021.2020043. Epub 2022 Feb 22. Hum Vaccin Immunother. 2022. PMID: 35192786 Free PMC article.
-
Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.mBio. 2021 May 18;12(3):e00855-21. doi: 10.1128/mBio.00855-21. mBio. 2021. PMID: 34006659 Free PMC article.
References
-
- Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. 2006. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103:10834–10839. doi:10.1073/pnas.0603940103. - DOI - PMC - PubMed
-
- Finne J, Bitter-Suermann D, Goridis C, Finne U. 1987. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 138:4402–4407. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources